** Shares of drugmaker Atara Biotherapeutics fall 47.8% to $6.87 premarket
** U.S. FDA has declined to approve company's cancer therapy tabelecleucel
** FDA's decision was based on observations made during an inspection of a third-party manufacturing facility for the therapy - company
** If ATRA does not secure enough funding by Q1 2025, it intends to suspend all of CAR-T cell therapy programs and significantly reduce expenses and activities to only those that support tabelecleucel's approval
** Shares rose 3.8% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。